cas 2637450-54-3|| where to buy 2-iodo-1-(2,2,2-trifluoroethyl)indol-4-amine;hydrochloride

Nom du produit:2-iodo-1-(2,2,2-trifluoroethyl)indol-4-amine;hydrochloride

IUPAC Name:2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine hydrochloride

: CAS：2637450-54-3; Formule moléculaire：C10H9ClF3IN2; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2637450-54-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2637450-54-3; Formule moléculaire:C10H9ClF3IN2; Point de fusion:-; Code SMILES:C1=CC(=C2C=C(N(C2=C1)CC(F)(F)F)I)N.Cl; Densité:

: Numéro de catalogue:CM1075497; Poids moléculaire:376.55; Point d'ébullition:; N° Mdl:; Stockage:

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: Rezatapopt; PMV Pharmaceuticals announced the latest results from a Phase 1/2 clinical trial of its potential first-in-class small molecule p53 reactivator rezatapopt (PC14586) for the treatment of patients with solid tumors. This candidate therapy is designed to selectively bind to the pocket of the TP53 Y220C mutant protein, thereby restoring wild-type or normal p53 protein structure and inhibiting tumor function. Previously, the US FDA granted PC14586 Fast Track designation for the treatment of patients with locally advanced or metastatic solid tumors carrying TP53 Y220C mutants.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.